Zantac Pulled From Shelves Due to Cancer Risks

Zantac Pulled From Pharmacy Shelves Due to Cancer Risks

The Food and Drug Administration Pulls Zantac From Pharmacy Shelves

Earlier this week, the U.S. Food and Drug Administration issued a news release requesting manufacturers to withdraw all products containing the popular heartburn drug, ranitidine, the active ingredient in the medication, Zantac . The order applies to both prescription and over-the-counter medications.

The recent recall is the latest step in an escalating investigation surrounding a contaminant known as N-Nitrosodimethylamine (NDMA), which is commonly found in ranitidine.

NDMA is listed as a well-known human carcinogen. At high levels, the substance can be very dangerous and life-threatening.

In 2019, the FDA discovered that NDMA was frequently found in ranitidine. Through recent third-party laboratory testing, the FDA confirmed that the level of NDMA in ranitidine was not only present in large amounts but could also increase over time, possibly reaching hazardous and lethal levels.

Have You Been Diagnosed with Cancer after Taking Zantac?

If you or a loved one has recently been diagnosed with stomach/gastric, liver, small intestine/colorectal, bladder, kidney, prostate, esophageal, or pancreatic cancer after taking Zantac or another heartburn medication containing ranitidine, contact Moll Law Group for immediate assistance.

Moll Law Group | molllawgroup.com